Lumretuzumab  (Synonyms: Anti-Human ERBB3 Recombinant Antibody)

Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Lumretuzumab (10 μM, 1 h) effectively inhibits HER2, HER3, and AKT phosphorylation after HRG stimulation in MCF-7 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lumretuzumab (10 mg/kg, i.p., once every week for 40-70 days) induces tumor arrest as a monotherapy in a mouse xenograft model of breast cancer with low ER+/HER2 expression, combined with Pertuzumab (HY-P9912) induces long-term tumor regression, and the efficacy is further improved upon the addition of Fulvestrant (HY-13636)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2065  [NCBI]

P21860

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.92 kDa

1448327-63-6

Liquid

Colorless to light yellow

[Lumretuzumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized HER3 Protein, Human (HEK293, His, HY-P72625) can bind Lumretuzumab. The EC₅₀ for this effect is 3.513 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ MCF-7 cells with Lumretuzumab (HY-P99304, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Schneeweiss A, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018 Oct;36(5):848-859.  [Content Brief]

  [2]. Collins D, et al. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLoS One. 2017 May 11;12(5):e0177331.  [Content Brief]